Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy.
BACKGROUND
Patients with hepatic malignancy have a dismal prognosis with standard therapies. NV1020 is an oncolytic herpes simplex virus that has potential to be a safe and effective therapeutic agent for this disease.


OBJECTIVE
We set out to discuss the development of NV1020 as an oncolytic agent and explore the potential role of this particular virus in the setting of human hepatic cancer.


METHODS
The scope of this review includes an overview of preclinical experience with NV1020, as well as an examination of current standard and developing therapies for liver cancer. The primary focus, however, is on the safety and potential clinical efficacy of NV1020 against hepatic malignancy.


CONCLUSIONS
We have found that NV1020 is a safe, novel therapeutic agent for treatment of refractory hepatic malignancy.
Memorial Sloan-Kettering Cancer Center, Department of Surgery, 1275 York Avenue, New York, NY 10065, USA.
Kaitlyn J
KJ
Kelly
Joyce
J
Wong
Yuman
Y
Fong
D000818:Animals; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D002986:Clinical Trials as Topic; D000529:Complementary Therapies; D006801:Humans; D008113:Liver Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D050130:Oncolytic Virotherapy; D018139:Simplexvirus / Q000276:immunology / Q000502:physiology*
D036022:Capsid Proteins; C121877:Norwalk virus capsid